|
|
Article: Dynavax's TOLAMBA(TM) Demonstrates Safety in Phase 1 Trial of Ragweed Allergic Children.
- Article from:
- PR Newswire
- Article date:
- November 7, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Presentation at ACAAI Confirms Same High Dose Level Can Be Used in Both Adults and Children
BERKELEY, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced presentation of data from a Phase 1 trial of its ragweed allergy immunotherapy, TOLAMBA, demonstrating that it was safe to test further in ragweed allergic children at a dose level equivalent to the regimen used in adults. TOLAMBA is currently being evaluated in two large- scale clinical trials. A two-year Phase 2/3 trial in adults is anticipated to yield data in the first quarter of 2006. A trial in 313 ragweed allergic children, designed to be supportive of the company's ...